breast cancer

October 20, 2025

The MICIU has allocated more than 76 million euros to breast cancer research since 2018.

The IIS Aragón is leading the "Unlocking Data Content of Organ-on-Chips" project, which focuses on studying the tumor environment and its response to breast cancer treatments.
30 July 2025

A new target has been identified to prevent metastasis in breast cancer.

A study points to the TIM-3 protein as a key factor in breast cancer cells' ability to metastasize. This finding suggests a new therapeutic approach to prevent this process before it becomes clinically apparent.
11 April 2025

4th Breast Cancer Humanization Conference in Zaragoza: "No one should feel alone in this process."

The meeting, held in the Patio de la Infanta and organized by the IIS Aragón, shared various experiences related to this disease that demonstrate the importance of humanization in the oncological process. Training, information, physical exercise, and a multidisciplinary approach are part of these examples of humanization.
10 April 2025

A special T-shirt after breast cancer surgery

Surgeons from Servet, together with the AECC in Zaragoza and Amac Gema, have designed a garment for patients leaving the hospital with drains. This initiative will be presented today at the 4th Aragonese Breast Cancer Humanization Conference, organized by the IIS Aragón in the Patio de la Infanta.
11 March, 2025

Registrations are now open for the IV Aragonese Conference on Humanization in Breast Cancer

"Discovering experiences" will take place on April 10 at the Patio de la Infanta of the Ibercaja Foundation in Zaragoza at 17:00 p.m. The IIS Aragón is organizing this event with free admission upon prior registration.
30 December, 2024

A new drug improves clinical outcomes for patients with advanced breast cancer

A Phase 3 clinical trial demonstrates that the combination of imlunestrant and abemaciclib improves progression-free survival in advanced ER+ HER2- breast cancer, regardless of genomic profile. The compound as monotherapy only shows benefits in patients with mutations in the ESR1 gene.